Acasti Pharma Inc V.ACST

Primary Symbol: ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Oppenheimer report on Acasti, outperform, target US $6

<< Previous

Bullboard Posts

Next >>

Comment by flush777on Jan 05, 2022 1:51pm

334 Views

Post# 34286028

RE:Oppenheimer report on Acasti, outperform, target US $6

ok, the issuance of the report triggered a rush to a high of $2.30 on Dec 22, 2021. I guess that the whole world knows of the report ... except that it takes time for analysis and thoughts and yes, I do believe that the stock is a good buy and I purchased after the stock fell from $2,30 to its level prior to its rise.

Here is a chart of the day high/low/close from Dec 21-24, fyi.

Close Prices Last 3 Months